Cemiplimab
(Redirected from Cemiplimab-rwlc)
Cemiplimab is a monoclonal antibody used in the treatment of certain types of cancer. It is marketed under the brand name Libtayo. Cemiplimab is specifically designed to target the programmed cell death protein 1 (PD-1) receptor, a protein found on the surface of T cells, which are a type of white blood cell involved in the immune response.
Mechanism of Action[edit | edit source]
Cemiplimab works by inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This interaction normally acts as a "brake" on the immune system, preventing T cells from attacking the body's own tissues. However, many tumors exploit this pathway to evade immune detection. By blocking PD-1, cemiplimab releases this brake, allowing T cells to recognize and destroy cancer cells more effectively.
Clinical Use[edit | edit source]
Cemiplimab is approved for the treatment of cutaneous squamous cell carcinoma (CSCC), a common form of skin cancer. It is indicated for patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or radiation. The drug is administered via intravenous infusion, typically every three weeks.
Development and Approval[edit | edit source]
Cemiplimab was developed by Regeneron Pharmaceuticals and Sanofi. It received FDA approval in 2018 for the treatment of advanced CSCC. The approval was based on clinical trials demonstrating significant tumor shrinkage in a substantial proportion of patients.
Side Effects[edit | edit source]
Common side effects of cemiplimab include fatigue, rash, and diarrhea. More serious immune-mediated side effects can occur, such as pneumonitis, hepatitis, and endocrinopathies. Patients receiving cemiplimab require monitoring for these adverse effects, and treatment may need to be adjusted or discontinued if severe reactions occur.
Research and Future Directions[edit | edit source]
Ongoing research is exploring the use of cemiplimab in other types of cancer, including non-small cell lung cancer (NSCLC) and basal cell carcinoma (BCC). Combination therapies with other immunotherapies or chemotherapy agents are also under investigation to enhance its efficacy.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju, Prab R. Tumpati, MD
